OncBioMune Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Baton Rouge, LA, specializing in innovative cancer research. The company is focused on developing novel cancer immunotherapy products, including a proprietary vaccine technology designed to stimulate the immune system to selectively attack cancer cells without harm to the patient.
Their lead product, ProscaVax, has shown promising results in prostate cancer patients, with successful completion of a Phase 1a trial funded by the Department of Defense Navy Cancer Vaccine Program. OncBioMune also has a portfolio of targeted therapies, including biosimilars to blockbuster drugs, aimed at providing effective treatment options for various types of cancer.
Generated from the website